Similar Efficacy and Safety With Subcutaneous Rituximab in Follicular Lymphoma

Share this content:
Subcutaneous rituximab has similar efficacy and safety as the intravenous formulation for the first-line treatment of follicular lymphoma.
Subcutaneous rituximab has similar efficacy and safety as the intravenous formulation for the first-line treatment of follicular lymphoma.

Subcutaneous rituximab has similar efficacy and safety as the intravenous (IV) formulation for the first-line treatment of follicular lymphoma (FL), according to a study published in Lancet Haematology.1

The standard of care for FL is IV rituximab, but its infusion lasts up to 6 hours. The purpose of this trial was to determine whether a subcutaneous formulation had non-inferior pharmacokinetics and a similar efficacy and safety profile.

The open-label, 2-stage, phase 3 SABRINA (ClinicalTrials.gov Identifier: NCT01200758) trial randomly assigned 410 adult patients with treatment-naïve CD20-positive, grade 1 to 3a FL to receive chemotherapy plus rituximab 375 mg/m2 IV or 1400 mg subcutaneously. All patients, however, received IV rituximab during their first cycle to evaluate for and manage adverse reactions.

The median age was 56.5; 86% of patients were white. The chemotherapy regimen contained cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) among 63% of patients, with the remaining 37% receiving cyclophosphamide, vincristine, and prednisolone (CVP). The majority of patients had grade 2 FL, followed by grade 1 and then grade 3a.

The overall response was similar in both groups, with 84.9% (95% CI, 79.2-89.5%) in the IV arm and 84.4% (95% CI, 78.7-89.1%) in the subcutaneous arm. Complete response was achieved by 66% in both arms.

The rate of grade 3 or higher adverse events (AEs) was 55% and 56% in the IV and subcutaneous arms, respectively, with the most common being neutropenia. The rate of serious AEs was also similar between arms (37% vs 35%, respectively). There were no new safety signals.

The rate of administration reactions was higher in the subcutaneous arm (48%) compared with the IV arm (35%), primarily due to grade 1 to 2 local injection-site reactions.

RELATED: Maintenance Rituximab for Follicular Lymphoma

According to the authors, these results indicate that “subcutaneous administration does not compromise the anti-lymphoma activity of rituximab when given with chemotherapy.”

Reference

  1. Davies A, Merli F, Mihaljevic B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 May 2. doi: 10.1016/S2352-3026(17)30078-9 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters